Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 14/20 | 0.61 |
| ▸ | BACE1 | P56817 | 13/20 | 0.61 |
| ▸ | ACHE | P22303 | 12/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058198 | 0.92 | SLC6A2 (0.60) | BCHEBACE1ACHESLC6A2SLC6A4 | |
| SCHEMBL24770749 | 0.89 | SLC6A2 (0.59) | BCHEBACE1ACHESLC6A2SLC6A4 | |
| SCHEMBL9634965 | 0.86 | BCHE (0.66) | BCHEBACE1ACHE | |
| SCHEMBL10025507 | 0.85 | BCHE (0.59) | BCHEBACE1ACHESLC6A2SLC6A4 | |
| SCHEMBL13541815 | 0.85 | BACE1 (0.61) | BCHEBACE1ACHESLC6A2SLC6A4 | |
| SCHEMBL12302951 | 0.84 | BCHE (0.71) | BCHEBACE1ACHE | |
| SCHEMBL11577003 | 0.83 | BCHE (0.69) | BCHEBACE1ACHESLC6A2SLC6A4 | |
| SCHEMBL4830474 | 0.82 | BCHE (0.68) | BCHEBACE1ACHE | |
| SCHEMBL4830468 | 0.82 | BCHE (0.68) | BCHEBACE1ACHE | |
| SCHEMBL6311588 | 0.82 | BCHE (0.54) | BCHEBACE1ACHESLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207173-B2 | Benzimidazoles and analogs thereof as antivirals | ISIS PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ISIS PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130513-A1 | BENZIMIDAZOLES AND ANALOGS THEREOF AS ANTIVIRALS | ZC3HAV1, NXF1, ZC3HAV1L | BCHE 4032/4885BACE1 2813/4885ACHE 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.